SUMMARY: OBJECTIVE: In a significant proportion of patients with hematologic malignancies (5-30%) poor mobilization of hematopoietic stem cells (HSC) is observed. This compromises the application of effective and potentially curative high-dose chemotherapy (HDC) treatment. CASE REPORT: Here we report the case of a 38-year-old female patient who was treated for recurrent follicular B-cell non-Hodgkin's lymphoma grade III. In this patient, we failed twice to mobilize stem cells using chemotherapy followed by granulocyte-colony stimulating factor (G-CSF). Recently a new chemokine receptor CXCR4 antagonist, AMD3100 (plerixafor), was introduced which can be combined with G-CSF mobilization and has been reported to increase the number of harvested stem cells significantly. Using this protocol, we were able to harvest a HSC product. This product was transplanted 3 weeks after the harvest (after HDC), and the patient had an uncomplicated recovery of granulopoiesis (day 11 after transplantation of autologous HSC). CONCLUSION: Plerixafor has the potency to become an important tool in mobilizing HSC, especially in those patients in whom HSC cannot be mobilized by the combination of G-CSF and chemotherapy alone.
SUMMARY: OBJECTIVE: In a significant proportion of patients with hematologic malignancies (5-30%) poor mobilization of hematopoietic stem cells (HSC) is observed. This compromises the application of effective and potentially curative high-dose chemotherapy (HDC) treatment. CASE REPORT: Here we report the case of a 38-year-old female patient who was treated for recurrent follicular B-cell non-Hodgkin's lymphoma grade III. In this patient, we failed twice to mobilize stem cells using chemotherapy followed by granulocyte-colony stimulating factor (G-CSF). Recently a new chemokine receptor CXCR4 antagonist, AMD3100 (plerixafor), was introduced which can be combined with G-CSF mobilization and has been reported to increase the number of harvested stem cells significantly. Using this protocol, we were able to harvest a HSC product. This product was transplanted 3 weeks after the harvest (after HDC), and the patient had an uncomplicated recovery of granulopoiesis (day 11 after transplantation of autologous HSC). CONCLUSION:Plerixafor has the potency to become an important tool in mobilizing HSC, especially in those patients in whom HSC cannot be mobilized by the combination of G-CSF and chemotherapy alone.
Authors: C Chabannon; A-G Le Corroller; F Viret; C Eillen; C Faucher; J-P Moatti; P Viens; N Vey; A-C Braud; G Novakovitch; P Ladaique; A-M Stoppa; J Camerlo; D Genre; D Maraninchi; D Blaise Journal: Leukemia Date: 2003-04 Impact factor: 11.528
Authors: A Corso; S Mangiacavalli; A Nosari; C Castagnola; P Zappasodi; A M Cafro; C Astori; M Bonfichi; M Varettoni; C Rusconi; D Troletti; C Pascutto; E Morra; M Lazzarino Journal: Bone Marrow Transplant Date: 2005-12 Impact factor: 5.483
Authors: S Fruehauf; G Ehninger; K Hübel; J Topaly; H Goldschmidt; A D Ho; S Müller; M Moos; K Badel; G Calandra Journal: Bone Marrow Transplant Date: 2009-07-13 Impact factor: 5.483
Authors: Maria Juliana Majado; Alfredo Minguela; Consuelo González-García; Eduardo Salido; Miguel Blanquer; Consuelo Funes; Carmen Luisa Insausti; Ana María García-Hernández; José María Moraleda; Alfonso Morales Journal: J Clin Apher Date: 2009 Impact factor: 2.821
Authors: W Conrad Liles; Hal E Broxmeyer; Elin Rodger; Brent Wood; Kai Hübel; Scott Cooper; Giao Hangoc; Gary J Bridger; Geoffrey W Henson; Gary Calandra; David C Dale Journal: Blood Date: 2003-07-10 Impact factor: 22.113